Show simple item record

dc.contributor.authorMa, Qing
dc.contributor.authorTobu, Mahmut
dc.contributor.authorSchultz, Christopher
dc.contributor.authorJeske, Walter
dc.contributor.authorHoppensteadt, Debra
dc.contributor.authorWalenga, Jeanine
dc.contributor.authorCornelli, Umberto
dc.contributor.authorLee, John
dc.contributor.authorLinhardt, Robert J.
dc.contributor.authorHanin, Israel
dc.contributor.authorFareed, Jawed
dc.date2007
dc.date.accessioned2022-06-23T03:58:49Z
dc.date.available2022-06-23T03:58:49Z
dc.date.issued2007-02-28
dc.identifier.citationMolecular Weight Dependent Tissue Factor Pathway Inhibitor Release by Heparin and Heparin Oligosaccharides, Q. Ma, M. Tobu, C. Schultz, W. Jeske, D. Hoppensteadt, J. Walenga, U. Cornelli, J. Lee, R. Linhardt, I. Hanin, J. Fareed, Thrombosis Research, 119, 653-661, 2007.
dc.identifier.issn493848
dc.identifier.urihttps://hdl.handle.net/20.500.13015/5208
dc.identifier.urihttps://doi.org/10.1016/j.thromres.2006.05.007
dc.descriptionThrombosis Research, 119, 653-661
dc.descriptionNote : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
dc.description.abstractHeparin and low molecular weight heparins exert their vascular effects by mobilizing tissue factor pathway inhibitor (TFPI) from the vascular endothelium into the blood circulation. We compared the influence of molecular weight on the TFPI release by heparin and its fractions in a non-human primate model. Primates were treated with unfractionated heparin, a low molecular weight heparin (gammaparin), or a heparin-derived oligosaccharide mixture (C3). Endothelial TFPI release was determined using both immunologic and functional assays. After intravenous administration, all agents significantly increased TFPI levels (p<0.05) in a dose dependent manner. The increase produced by unfractionated heparin and gammaparin was greater than that by C3 at an equal dosage (p<0.05). With subcutaneous injection, all agents produced less TFPI release. Repeated administration of heparin-derived oligosaccharides gradually increased TFPI release. A 1.89 fold increase in TFPI levels was observed 4 days after C3 treatment (2.5 mg/kg). Our findings indicated that TFPI release is dependent on the molecular weight of heparin and its derivatives. Heparin oligosaccharides exert their vascular effects through increased TFPI release after long-term repeated administration.
dc.description.sponsorshipNational Heart, Lung, and Blood Institute
dc.languageen_US
dc.language.isoENG
dc.publisherElsevier
dc.relation.ispartofThe Linhardt Research Labs Online Collection
dc.relation.ispartofRensselaer Polytechnic Institute, Troy, NY
dc.relation.ispartofThrombosis Research
dc.relation.urihttps://harc.rpi.edu/
dc.subjectBiology
dc.subjectChemistry and chemical biology
dc.subjectChemical and biological engineering
dc.subjectBiomedical engineering
dc.titleMolecular Weight Dependent Tissue Factor Pathway Inhibitor Release by Heparin and Heparin Oligosaccharides
dc.typeArticle
dcterms.accessRightsA full text version is available in DSpace@RPI
dcterms.isPartOfJournal
dcterms.isVersionOfhttps://doi.org/10.1016/j.thromres.2006.05.007
dc.rights.holderIn Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). https://rightsstatements.org/page/InC/1.0/
dc.creator.identifierhttps://orcid.org/0000-0003-2219-5833
dc.relation.departmentThe Linhardt Research Labs.
dc.relation.departmentThe Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)
rpi.description.pages653-661
rpi.description.volume119


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record